Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase III Clinical Trial for Pediatric Crohn’s Disease

Statera Biopharma, Inc. announced that it has received Central Institutional Review Board approval to conduct a Phase III clinical trial for STAT-201 in the treatment of pediatric Crohn’s Disease, a chronic relapsing inflammatory condition of the gastrointestinal tract.